BIOTON Competitors and Similar CompaniesClear all
BIOTON's competitors and similar companies include Novaremed, Pila Pharma, Kadimastem and ARKAY.
 Kadimastem Kadimastem is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells (hESCs). |  ARKAY ARKAY is a pharmaceutical company that develops RK-01, an orally-active pancreatic beta-cell-centric combination product that provides sustained glycemic control for patients with Type 2 diabetes. | ||||
Founding Date | Founding Date 1989 | Founding Date 2017 | Founding Date 2014 | Founding Date 2009 | Founding Date 2014 |
Type | Type Public | Type Private | Type Private | Type Public | Type Private |
Tags | |||||
Locations | Locations Macierzysz, PL HQ | Locations Basel, CH HQ | Locations Malmö, SE HQ | Locations Ness Ziona, IL HQ | Locations Windsor, US HQ |
Employees | Employees 361 | Employees 10 | Employees 9 | Employees 11 | Employees 1 |
Financial | |||||
Revenue (est.) | Revenue (est.) zł282.5m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods zł157.1m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit zł128.4m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income zł3.4m (FY, 2025) | Net income N/A | Net income N/A | Net income (₪26.6m) (FY, 2024) | Net income N/A |
For sources of this data, please see the company profile
View Company Profiles
Kadimastem
HQ
Ness Ziona, IL
Employees
11
Kadimastem is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells (hESCs).
View companyARKAY
HQ
Windsor, US
Employees
1
ARKAY is a pharmaceutical company that develops RK-01, an orally-active pancreatic beta-cell-centric combination product that provides sustained glycemic control for patients with Type 2 diabetes.
View company